Mark J. Mihanovic, head of the Firm’s California Corporate group and head of the Emerging Companies/Venture Capital group, focuses his practice primarily in the areas of corporate finance and mergers and acquisitions. He represents companies in a broad range of industries, with a particular emphasis on technology, life science and health care companies. Mark serves as corporate liaison partner in the Firm’s strategic alliance with MWE China Law Offices based in Shanghai.
Mark serves as lead counsel on behalf of issuers and underwriters in public offerings and private placements (including private investments in public equities (PIPEs)) of equity and debt securities. He handles stock and asset acquisitions, divestitures, mergers, proxy fights and joint ventures and has had primary oversight responsibility for the regional and worldwide acquisition programs of multiple clients. Mark represents early-stage companies in connection with formation and organizational issues and venture capital and other financings and has also represented investors in complex venture capital transactions involving equity and debt.
Mark has substantial experience advising corporate boards of directors and management regarding fiduciary duties (including in connection with potential change in control transactions and consideration of “poison pill” stockholders rights plans) and corporate governance issues. He assists publicly traded companies with their Securities and Exchange Commission filings and other securities compliance matters. He also advises investment banks on securities compliance issues and in acting as financial adviser and delivering fairness opinions in the context of acquisitions and restructurings.
Mark has lectured at various external and McDermott-sponsored programs on the topic of public offerings and on emerging company issues. He has also spoken on mergers and acquisitions and other corporate law-related topics in various client seminars and has served as guest lecturer for transaction-related courses at the University of Michigan Law School and Stanford Law School.
Represented Apollo Medical Holdings, Inc. (a publicly traded physician practice management company) in its business combination transaction (valued at approximately $300 million) with Network Medical Management, Inc.
Represented Ascension Health Alliance in various projects, including the following:
A joint venture in the Cayman Islands with an India-based company
The acquisition of Michigan-based US Health Holdings, Ltd. for $50 million
Represented the UK-based beverage company C&C Group plc (i) in its acquisition of the Hornsby’s cider brand from E&J Gallo Winery and (ii) in connection with its US distribution and sales operations deal with Pabst Brewing Company
Represented Corindus Vascular Robotics, Inc. is an approximately $50 million underwritten public offering
Represent Fowler Property Acquisitions (a San Francisco-based real estate company) in the formation and capitalization of new real estate investment funds (including real estate investment trusts (REITs))
Represented iSubscribed Inc. (a digital security company) in a multi-part transaction involving (i) the formation by iSubscribed and two equity investors of a buyer entity to effect a tender offer acquisition of Intersections, Inc. and (ii) the subsequent business combination of iSubscribed with the buyer entity and Intersections
Represented Intuitive Surgical, Inc. in connection with a joint venture in China with Chinese conglomerate Fosun
Represent surf- and snow-wear company O’Neill, Inc. in (i) the sale of its worldwide trademark portfolio and other assets to SISCO Textiles NV and (ii) other general transactional matters
Represent Premier, Inc. in the following:
Its Up-C reorganization and approximately $900 million initial public offering
Its $120 million Company-Directed Offering by selling member-owner stockholders
Its $140 million Company-Directed Offering by selling member-owner stockholders
As general outside securities and corporate governance counsel
Represented QuantumWise (a Denmark-based software company) in connection with its sale to Synopsys
Represented Virttu Biologics Ltd. (a UK-based life sciences company) in its sale to Sorrento Therapeutics, Inc.
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.